The Serum Epitope Repertoire Analysis (SERA) platform is a universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify the antigens and epitopes associated with many diseases – all in a single assay.


Unlimited Multiplexing

Simultaneous profiling of multiple pathogens from a single specimen

Exquisitely High-Resolution

Epitope mapping in infectious diseases, oncology and autoimmune disease

Clinically Relevant Analysis

State-of-the-Art Database with 26,000+ profiled antibody repertoires from individuals with disease as well as healthy blood donors

Scientific Support

Leading experts in epitope analysis and bioinformatics

Ideal for

Epitope Mapping

Target Identification

Disease Stratification

Response Measurement

Immune Response Infection

Autoimmune Biomarkers

Cancer Detection

Serum Epitope Repertoire Analysis (SERA) Platform

Combining  universal chemistry with proprietary informatics, SERA assesses antibody repertoires to address research and clinical needs.

Two Complementary Bioinformatics Methods

Identify epitopes (PIWAS) and motifs (IMUNE) associated with disease.


SERA provides value across multiple areas of Academic, Industry and Government research.

Disease Categories

Autoimmune Disease


Infectious Disease


Uncover novel epitopes

Discover unique and specific antigens

Unmask disease associations

Develop novel biomarkers

Profile patients' immune response

Stratify patients


Serimmune partners with academic institutions, biopharma and healthcare organizations and government that seek to power immune-related research, product development and to make healthcare decisions.

The SERA platform has features that make it robust and ideal for biomarker discovery, clinical diagnostic panel development, serologic surveillance.

Partner With Us

Autoimmune Disease

SERA has been used to identify both validated and potentially novel antigens in multiple autoimmune disorders. Candidate autoantigens in cohorts may help distinguish sub-types of disease or help to predict/track response to therapy, identify new targets, and enable precision immunology.


Using SERA, researchers can identify candidate autoantigens that may be used as biomarkers for diagnosis, sub-typing, or monitoring in oncology. B cell response in immuno-oncology has recently been highlighted in association with response to checkpoint inhibitor therapy. SERA enables the tracking of potential autoantigen signals before and after therapy to identify candidate biomarkers of response to therapy, paving the way for precision oncology.

Infectious Disease

SERA can identify the most significant antigens in infections for diagnostic and therapeutic target discovery as demonstrated in COVID-19. Using cohorts with disease, SERA can also identify sensitive and specific peptides for infections that can be used on alternate diagnostic platforms.


SERA is a powerful tool that pharmaceutical and biotech organizations can leverage for identification of motifs and peptide epitopes recognized by monoclonal antibodies. These can be used to optimize the selection of therapeutic candidates. SERA has also identified the antigenic targets of antibody repertoires to identify therapeutic targets. This screening may identify potential off-target antigens for our partners.

Population Serosurveillance

SERA has the broad potential to enable dynamic monitoring and surveillance for hundreds of diseases in one assay. It has recently been used to demonstrate the increase in seropositivity early in the COVID-19 epidemic. Significantly, SERA has also demonstrated the ability to detect seropositivity retrospectively and in silico, without the need of any new assays, enabling serosurveillance in individuals and populations for a variety of emerging infections.